Doxorubicin anti-tumor mechanisms include Hsp60 post-translational modifications leading to the Hsp60/p53 complex dissociation and instauration of replicative senescence. (28th January 2017)
- Record Type:
- Journal Article
- Title:
- Doxorubicin anti-tumor mechanisms include Hsp60 post-translational modifications leading to the Hsp60/p53 complex dissociation and instauration of replicative senescence. (28th January 2017)
- Main Title:
- Doxorubicin anti-tumor mechanisms include Hsp60 post-translational modifications leading to the Hsp60/p53 complex dissociation and instauration of replicative senescence
- Authors:
- Marino Gammazza, Antonella
Campanella, Claudia
Barone, Rosario
Caruso Bavisotto, Celeste
Gorska, Magdalena
Wozniak, Michal
Carini, Francesco
Cappello, Francesco
D'Anneo, Antonella
Lauricella, Marianna
Zummo, Giovanni
Conway de Macario, Everly
Macario, Alberto J.L.
Di Felice, Valentina - Abstract:
- Abstract: The chaperone Hsp60 is pro-carcinogenic in certain tumor types by interfering with apoptosis and with tumor cell death. In these tumors, it is not yet known whether doxorubicin anti-tumor effects include a blockage of the pro-carcinogenic action of Hsp60. We found a doxorubicin dose-dependent viability reduction in a human lung mucoepidermoid cell line that was paralleled by the appearance of cell senescence markers. Concomitantly, intracellular Hsp60 levels decreased while its acetylation levels increased. The data suggest that Hsp60 acetylation interferes with the formation of the Hsp60/p53 complex and/or promote its dissociation, both causing an increase in the levels of free p53, which can then activate the p53-dependent pathway toward cell senescence. On the other hand, acetylated Hsp60 is ubiquitinated and degraded and, thus, the anti-apoptotic effect of the chaperonin is abolished with subsequent tumor cell death. Our findings could help in the elucidation of the molecular mechanisms by which doxorubicin counteracts carcinogenesis and, consequently, it would open new roads for the development of cancer treatment protocols targeting Hsp60. Highlights: Low doxorubicin doses induce replicative senescence in human lung mucoepidermoid carcinoma cells. Cells treated with doxorubicin show a reduction of Hsp60 levels and an increase in its acetylation. Hsp60 acetylation may induce the destabilization of the pro-tumor Hsp60/p53 complex in these cells. p53 may exertAbstract: The chaperone Hsp60 is pro-carcinogenic in certain tumor types by interfering with apoptosis and with tumor cell death. In these tumors, it is not yet known whether doxorubicin anti-tumor effects include a blockage of the pro-carcinogenic action of Hsp60. We found a doxorubicin dose-dependent viability reduction in a human lung mucoepidermoid cell line that was paralleled by the appearance of cell senescence markers. Concomitantly, intracellular Hsp60 levels decreased while its acetylation levels increased. The data suggest that Hsp60 acetylation interferes with the formation of the Hsp60/p53 complex and/or promote its dissociation, both causing an increase in the levels of free p53, which can then activate the p53-dependent pathway toward cell senescence. On the other hand, acetylated Hsp60 is ubiquitinated and degraded and, thus, the anti-apoptotic effect of the chaperonin is abolished with subsequent tumor cell death. Our findings could help in the elucidation of the molecular mechanisms by which doxorubicin counteracts carcinogenesis and, consequently, it would open new roads for the development of cancer treatment protocols targeting Hsp60. Highlights: Low doxorubicin doses induce replicative senescence in human lung mucoepidermoid carcinoma cells. Cells treated with doxorubicin show a reduction of Hsp60 levels and an increase in its acetylation. Hsp60 acetylation may induce the destabilization of the pro-tumor Hsp60/p53 complex in these cells. p53 may exert its tumor suppressive function by activating p53-dependent cell senescence pathway via the induction of p21. … (more)
- Is Part Of:
- Cancer letters. Volume 385(2017)
- Journal:
- Cancer letters
- Issue:
- Volume 385(2017)
- Issue Display:
- Volume 385, Issue 2017 (2017)
- Year:
- 2017
- Volume:
- 385
- Issue:
- 2017
- Issue Sort Value:
- 2017-0385-2017-0000
- Page Start:
- 75
- Page End:
- 86
- Publication Date:
- 2017-01-28
- Subjects:
- Doxorubicin -- Hsp60 -- Acetylation -- Ubiquitination -- p53 -- Replicative senescence
DMSO dimethylsulfoxide -- ELISA enzyme linked immunosorbent assay -- GAPDH glyceraldehyde-3-phosphate dehydrogenase -- GUSB betaglucuronidase -- HDAC histone deacetylases -- H2AX H2A histone family member X -- HPRT1 hypoxanthine phosphoribosyltransferase 1 -- Hsps heat shock proteins -- MTT 3-(4, 5-dimethylthiazol-2-yl)-2, 3-diphenyltetrazolium bromide -- OD optical density -- RS replicative senescence -- SA-β-gal senescence-associated β-galactosidase -- Sirt3 sirtuin 3 -- 17AAG 17-(Allylamino)-17-demethoxygeldanamycin
Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Electronic journals
616.994 - Journal URLs:
- http://www.sciencedirect.com/science/journal/03043835/ ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.canlet.2016.10.045 ↗
- Languages:
- English
- ISSNs:
- 0304-3835
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3046.485000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 810.xml